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Abstract
Friedreich’s ataxia (FA) is a crippling neurodegenerative disease that is due to iron (Fe) overload within the
mitochondrion. One therapeutic intervention may be the development of a chelator that could remove mitochondrial Fe. We
have implemented the only well characterized model of mammalian mitochondrial Fe overload to examine the Fe chelation
efficacy of novel chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone (PCIH) class. In this model we utilize
reticulocytes treated with the haem synthesis inhibitor succinylacetone which results in mitochondrial Fe-loading. Our
experiments demonstrate that in contrast to desferrioxamine, several of the PCIH analogues show very high activity at
mobilizing 59Fe from 59Fe-loaded reticulocytes. Further studies on these ligands in animals are clearly warranted considering
their potential to treat FA. ß 2001 Elsevier Science B.V. All rights reserved.
Keywords: Chelator; Desferrioxamine; Friedreich’s ataxia; Iron; Iron overload disease; Pyridoxal isonicotinoyl hydrazone
1. Introduction
Friedreich’s ataxia (FA) is a severe neurodegener-
ative condition [1,2]. In 97% of patients the disease is
due to a GAA triplet repeat expansion in intron 1 of
the FRDA gene resulting in a marked decrease in its
expression [1,2]. The protein encoded by this gene is
known as frataxin and is located within the mito-
chondrion [2,3]. Over the last few years evidence
has accumulated to suggest that frataxin plays a
role in mitochondrial Fe metabolism [2,4^10]. Stud-
ies using the yeast cell showed that deletion of the
homologous gene (YFH1) resulted in an accumula-
tion of mitochondrial Fe resulting in the loss of mi-
tochondrial DNA, Fe-sulphur cluster-containing en-
zymes, and respiration [4^6,11]. Like the human
FRDA gene, YFH1 encodes a mitochondrial protein
(Yfh1p). When YFH1 was reintroduced back into
the yeast, mitochondrial Fe was exported back out
into the cytosol, suggesting a ‘mitochondrial Fe
cycle’ [4,9].
Consistent with the knockout yeast model, Bradley
et al. [10] noted reductions in mitochondrial DNA,
complex I, complex II/III, and aconitase in the heart
of FA patients, observations consistent with mito-
chondrial damage. In addition, these authors re-
ported increased Fe deposition in the heart, liver,
and spleen of FA patients in a pattern consistent
with a mitochondrial location [10]. This evidence
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suggesting that FA is caused by mitochondrial Fe
overload was supported by work showing Fe depos-
its within the heart myo¢brils [12,13], defective my-
ocardial and skeletal muscle mitochondrial respira-
tion [8,11], and perturbations in the haem synthesis
pathway [14].
Since the pathology of FA is linked to mitochon-
drial Fe overload, new therapies based on these re-
sults could provide hope for FA patients. One novel
strategy is the use of speci¢c Fe chelators that can
permeate the mitochondrion. A trial supported by
the National Institute of Health is already investigat-
ing the use of the clinically used Fe chelator desfer-
rioxamine (DFO) to treat FA patients [15]. How-
ever, DFO cannot e⁄ciently mobilize Fe from cells
[16,17], and it is not e¡ective at mobilizing Fe from
Fe-loaded mitochondria [18,19].
In contrast to DFO, Ponka and associates [18,20]
have demonstrated that another chelator, pyridoxal
isonicotinoyl hydrazone (PIH; Fig. 1), shows high
activity at mobilizing Fe from an experimental model
of mitochondrial Fe overload in reticulocytes. A va-
riety of studies, in vitro, in vivo, and a clinical trial,
have shown that PIH and its analogues show high
potential for the treatment of Fe overload disease
([18,20^23]; for review see [24]). Unfortunately, the
development of PIH was hindered due to the fact
that it was not patented, resulting in little interest
from the pharmaceutical industry [24]. To overcome
this disadvantage we have synthesized a new group
Fig. 1. The structures of the iron chelators assessed in this study: desferrioxamine (DFO), pyridoxal isonicotinoyl hydrazone (PIH),
2-pyridylcarboxaldehyde isonicotinoyl hydrazone (PCIH), 2-pyridylcarboxaldehyde m-bromobenzoyl hydrazone (PCBBH), 2-pyridylcar-
boxaldehyde thiophenecarboxyl hydrazone (PCTH), 2-pyridylcarboxaldehyde p-hydroxybenzoyl hydrazone (PCHH), 2-pyridylcarboxal-
dehyde p-aminobenzoyl hydrazone (PCAH), and 2-furoylcarboxaldehyde isonicotinoyl hydrazone (FIH).
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of ligands known as the 2-pyridylcarboxaldehyde iso-
nicotinoyl hydrazone (PCIH) analogues (Fig. 1)
[25,26]. These compounds have patent protection
and were designed to share structural similarities to
PIH (see Fig. 1). Moreover, several PCIH analogues
were more active than DFO or PIH at mobilizing
59Fe from the SK-N-MC neuroepithelioma cell line,
and showed low antiproliferative activity [25]. Obvi-
ously, both these latter properties are essential for
the long-term treatment of Fe overload disease.
In the present study we have utilized the only well
characterized cellular model of mitochondrial Fe
overload, namely reticulocytes treated with the spe-
ci¢c haem synthesis inhibitor, succinylacetone (SA)
[27^31]. It is well established that in erythroid cells
Fe is targeted to the mitochondrion for haem syn-
thesis [31,32]. Succinylacetone is a competitive inhib-
itor of the enzyme N-aminolevulinic acid dehydratase
and prevents protoporphyrin production [27]. Hence,
in the presence of SA, Fe cannot be incorporated
into protoporphyrin to form haem and results in
an accumulation of non-haem mitochondrial Fe
[28^33]. This provides a convenient model for assess-
ing the ability of chelators to permeate this organelle
and remove Fe [18^20,33]. The results of the present
investigation demonstrate that several PCIH ana-
logues are very e¡ective at mobilizing mitochondrial
Fe. Consequently, we suggest that these ligands de-
serve further vigorous investigation as agents for the
potential treatment of FA.
2. Materials and methods
2.1. Chelators
DFO was purchased from Novartis Pharmaceuti-
cals (Switzerland). The PCIH analogues and PIH
(Fig. 1) were synthesized by Schi¡ base condensation
and characterized by elemental analysis, infrared
spectroscopy, 1H-NMR, and X-ray crystallography
as described previously [18,20,25,26].
2.2. Reticulocytes
Reticulocytosis was induced in CD1 mice by in-
jecting phenylhydrazine [33] using a protocol ap-
proved by the McGill University Animal Care Com-
mittee. Mice were injected with phenylhydrazine once
per day for 3 days and the animals sacri¢ced 4 days
after the last injection. Blood was obtained by car-
diac puncture using a heparinized needle. Reticulo-
cytes were identi¢ed based on staining with new
methylene blue, and cell counts were determined us-
ing an improved Neubauer counting chamber. All
preparations consisted of 30^35% reticulocytes and
all samples used were free of haemolysis. Cell viabil-
ity was assessed by microscopic examination of the
reticulocytes for lysis and the detection of released
haemoglobin into the supernatant.
2.3. Labelling of transferrin
Apotransferrin (Sigma, St. Louis, MO, USA) was
prepared and labelled with 59Fe (as ferric chloride in
0.1 M HCl, Dupont NEN, MA, USA) to produce
59Fe2-transferrin (59Fe-Tf) using established methods
[34].
2.4. Mobilization of 59Fe from 59Fe-loaded
reticulocytes
Reticulocytes were obtained as described above
and incubated with 1 mM SA (Sigma) in minimum
essential medium (MEM; Gibco, Grand Island, NY,
USA) to inhibit haem synthesis [27^31]. After a 30
min preincubation at 37‡C in the presence of SA,
59Fe-Tf (10 WM) was added and incubated with the
cells for 1 h at 37‡C in a shaking water bath. A 30
min incubation with SA has been shown previously
to result in marked mitochondrial Fe accumulation
and that su⁄cient 59Fe is incorporated after a 1 h
label with 59Fe-Tf [28,35].
The reticulocytes were subsequently washed three
times with ice-cold PBS to remove non-speci¢cally
bound 59Fe-Tf. The washed 59Fe-labelled reticulo-
cytes (30^35 Wl) were then incubated with shaking
at 37‡C in MEM (500 Wl ¢nal volume) with the li-
gands (10^200 WM) for 15^240 min. The SA (1 mM)
was present in all incubations with the chelators to
prevent the utilization of non-haem 59Fe for haem
synthesis [35]. The 59Fe was measured in washed re-
ticulocytes and in the medium, and the 59Fe release
(counts per minute; cpm) was calculated as a per-
centage of the total number of cpm originally found
in the cells [18,20]. Radioactivity was measured using
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a Q-counter with background correction (LKB 1282
Compugamma, Finland).
After the incubation with the chelators, the e¥ux
medium was removed and the 59Fe-labelled reticulo-
cytes were lysed by incubating reticulocytes for 15
min with 200 Wl of ice-cold doubly distilled water.
The proteins were then precipitated with 1 ml of
ice-cold 95% ethanol. The resulting suspension was
then centrifuged (13 000 rpm/30 min/4‡C) on an IEC
Micromax microcentrifuge (IEC, Canada) to result
in an ethanol-soluble fraction containing 59Fe-bound
to the chelators, and an ethanol-precipitated fraction
containing protein-bound 59Fe [33,36]. Previous stud-
ies have demonstrated that this method results in the
precipitation of 59Fe in ferritin and Tf while 59Fe
bound to chelators remains in a soluble form [33,
36]. An increase of 59Fe in the ethanol-soluble frac-
tion shows that the chelator can cross the cell mem-
brane and form intracellular 59Fe complexes which
are released with limited e⁄ciency [36].
3. Results
In this investigation we have examined the Fe che-
lation e⁄cacy of the PCIH analogues using the only
well characterized model of mitochondrial Fe over-
load, that is, reticulocytes loaded with mitochondrial
non-haem 59Fe [18^20,28^33]. In all studies PIH was
used as our reference compound as this chelator has
been characterized in previous studies to e¡ectively
deplete the non-haem mitochondrial Fe pool [18,
20,33].
In initial studies the e¡ect of reincubation time on
59Fe release from Fe-loaded reticulocytes was as-
sessed (Fig. 2). In these experiments cells were la-
belled with 59Fe-Tf for 1 h at 37‡C, washed, and
then reincubated for up to 240 min in the presence
and absence of the chelators (200 WM). Of the eight
compounds examined, PCIH was the most e¡ective
at increasing cellular 59Fe release as a function of
incubation time (Fig. 2). Indeed, PCIH was more
e¡ective than PIH during incubation periods from
15 to 120 min, but had similar activity after a 240
min reincubation. The high activity of PCIH was
evident after only 15 min incubation with 59Fe-
loaded reticulocytes, at which point the compound
had mobilized 21 þ 1% (three determinations) of cel-
lular 59Fe (Fig. 2). The amount of 59Fe released by
PCIH after 15 min was more than that mobilized by
PCBBH, PCAH, PCHH, or FIH after 240 min of
incubation, viz. 17%, 15%, 6%, and 4% respectively
(Fig. 2). Desferrioxamine was the least e¡ective che-
lator examined in terms of its ability to mobilize 59Fe
from 59Fe-loaded reticulocytes, being only slightly
more e¡ective than control medium (Fig. 2). In all
Fig. 2. The e¡ect of reincubation time with the Fe chelators on
59Fe mobilization from 59Fe-loaded reticulocytes. The cells were
labelled with 59Fe-transferrin (10 WM) for 1 h at 37‡C in the
presence of the haem synthesis inhibitor SA (1 mM). The 59Fe-
labelled reticulocytes were then washed and incubated with the
chelators (200 WM) in the presence of SA (1 mM) for 15^240
min at 37‡C. The results are mean þ S.D. (three determinations)
in a typical experiment of three performed.
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experiments, the 59Fe released was ethanol-soluble,
indicating that it is a low molecular weight complex
that is not bound to protein.
None of the chelators had any e¡ect on cellular
viability over all incubations tested, and the 59Fe
release was not due to the chelators inducing cell
lysis. Examination of the ethanol-soluble intracellu-
lar 59Fe after incubation with the chelators revealed
that this only increased in the presence of FIH (Fig.
3), suggesting the possible accumulation of its 59Fe
complex within the cell. We did not see any accumu-
lation of the 59Fe-PCIH complex in the ethanol-solu-
ble fraction (Fig. 3), probably because the chelator
quickly di¡uses into the cell and then the complex
rapidly exits out into the supernatant. In the case of
PCIH and some of the highly active chelators (e.g.
PIH and PCTH), the process of entry and exit from
the cell is probably rapid, with a steady-state low
intracellular ligand concentration becoming estab-
lished. The appropriate lipophilicity of these com-
pounds is probably an important criterion in this
regard [25].
In further studies the e¡ect of chelator concentra-
tion was assessed on 59Fe mobilization from 59Fe-
loaded reticulocytes. In these experiments the cells
were labelled with 59Fe-Tf for 1 h at 37‡C, washed,
and then reincubated for 1 h at 37‡C in the presence
and absence of the chelators (Fig. 4). Again, PCIH
was the most active chelator. At a concentration of
200 WM, PCIH released 31 þ 1% (three determina-
tions) of cellular 59Fe compared to PIH that mobi-
lized 18 þ 1% (three determinations) (Fig. 4). The
compound PCTH had similar Fe chelation e⁄cacy
as PIH, while the remaining ligands were substan-
tially less e⁄cient (Fig. 4). As described previously
[18,19], DFO even at high concentrations up to 5 mM
had little e¡ect on mobilizing 59Fe, having an activity
similar to that observed with control medium. Sim-
ilar to our previous studies using the SK-N-MC neu-
roepithelioma cell line [25], both FIH and PCHH
showed very low activity at mobilizing intracellular
59Fe (Fig. 4). As illustrated in Fig. 3, an increase in
ethanol-soluble intracellular 59Fe was only observed
with FIH, and this increased as the concentration
was raised up to 200 WM (data not shown).
4. Discussion
At present there is no treatment which totally pre-
vents the pathogenesis of FA. The exciting ¢nding
that mitochondrial Fe accumulation may play an
important role in its pathogenesis [2,4^10] suggests
that one possible therapeutic intervention may be
Fe chelation therapy. This study identi¢es some of
the PCIH class of chelators as highly e¡ective ligands
for mobilizing mitochondrial non-haem Fe from re-
ticulocytes. This latter model was used as it is the
only well characterized system of mitochondrial Fe
overload in cells [28^33]. Previous studies from our
laboratories and others have shown that incubation
Fig. 3. The e¡ect of reincubation time with the Fe chelators on
the percentage of ethanol-soluble 59Fe in reticulocytes. The cells
were treated as in Fig. 2 and the percentage of ethanol-soluble
59Fe determined by lysing 59Fe-labelled reticulocytes with ice-
cold doubly distilled water. The proteins were precipitated using
ice-cold 95% ethanol and the soluble and insoluble fractions
were separated by centrifugation (see Section 2). The results are
mean þ S.D. (three determinations) in a typical experiment of
three performed.
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of reticulocytes with haem synthesis inhibitors such
as SA results in a very marked accumulation of
mitochondrial non-haem 59Fe [18,19,28^31,33,35].
This mitochondrial Fe has been shown to be bound
by some chelators of the PIH class [18,19,33,35], and
this obviously provides an appropriate model to
test potential ligands for the treatment of FA. It
is relevant to note that reticulocytes treated with
59Fe-Tf in the absence of haem synthesis inhibitors
do not accumulate mitochondrial non-haem 59Fe,
as it is e⁄ciently incorporated into haem that can-
not be accessed and mobilized by the chelators [18,
19].
The ability of PCIH and PCTH to mobilize mito-
chondrial Fe pools overcomes the disadvantage of
DFO that cannot e¡ectively deplete Fe from this
compartment [18,19]. These studies complement our
previous work demonstrating the high chelation
e⁄cacy and low toxicity of the PCIH group of li-
gands in the SK-N-MC neuroepithelioma cell line
[25]. Indeed, some of these compounds were far
more e⁄cient than DFO at increasing Fe mobiliza-
tion from cells and preventing Fe uptake from Tf
[25].
The PCIH class of chelators was speci¢cally de-
signed based upon our previous studies on a wide
range of compounds of the PIH class [35,37,38].
From these studies structural features critical for
high chelation e⁄cacy and low toxicity were chosen
to optimize the use of these ligands as agents to treat
Fe overload disease. Indeed, our design strategy has
been successful, as it has resulted in chelators that
show higher activity than the parent compound PIH
(this study and [25]).
The strategy to design new chelators derived from
PIH was based upon the advantageous properties of
this ligand. These are: (1) oral e¡ectiveness; (2) near
optimal hydrophilic-lipophilic balance; (3) high spe-
ci¢city and selectivity for Fe; (4) predominantly neu-
tral at physiological pH; (5) economical and simple
to synthesize; and (6) high chelation e⁄cacy both in
vitro and in vivo (for review see [24]). These new
patented chelators were essential to synthesize, as
the development of ligands as therapeutic agents re-
quires commercial intervention. Unfortunately, PIH
was never patented, which made it an unattractive
candidate for development by the pharmaceutical in-
dustry.
The potential for the use of Fe chelators as agents
to treat FA is suggested by a recent clinical trial
examining the e¡ect of DFO in these patients [15].
Although this trial is vital to perform, it should be
noted that DFO is quite a hydrophilic drug that does
not e⁄ciently permeate plasma membranes to bind
Fig. 4. The e¡ect of chelator concentration on 59Fe mobiliza-
tion from 59Fe-loaded reticulocytes. The cells were labelled with
59Fe-transferrin (10 WM) for 1 h at 37‡C in the presence of the
haem synthesis inhibitor SA (1 mM). The 59Fe-labelled reticulo-
cytes were washed and then incubated with the chelators (10^
200 WM) in the presence of SA (1 mM) for 60 min at 37‡C.
The results are mean þ S.D. (three determinations) in a typical
experiment of three performed.
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cytosolic Fe [16,17]. Hence, DFO may not be able to
e⁄ciently permeate mitochondrial membranes, and
this is a question that requires further investigation.
Certainly, in this study (Figs. 2 and 4) and previous
investigations [18,19], DFO had little e¡ect at mobi-
lizing mitochondrial Fe, even at very high clinically
unachievable concentrations (5 mM) [18,19]. The
other problems with DFO therapy, namely its poor
intestinal absorption that necessitates long s.c. infu-
sion (12^24 h/day, 5^6 days/week) and high cost, are
serious disadvantages that necessitate development of
an orally e¡ective chelator [39].
The reason for the ability of some of the PCIH
ligands to mobilize mitochondrial Fe may be their
much higher lipophilicity in comparison to DFO. In-
deed, to permeate the mitochondrion and chelate Fe,
three lipid membranes need to be transversed, viz.,
the plasma membrane and the inner and outer mito-
chondrial membranes. Obviously, a lipophilic chela-
tor that rapidly permeates membranes and targets
mitochondrial Fe will be far more e¡ective than a
hydrophilic compound such as DFO. This may be
a critical property of the ligand, since the Fe loading
in FA is not as pronounced as that found in un-
treated L-thalassaemia. Hence, only very short dura-
tions of therapy may be possible or necessary in or-
der to prevent overall body Fe depletion. Under
these conditions, speci¢c targeting of mitochondrial
Fe pools will be a vital property. Indeed, perhaps
combination of Fe chelators with antioxidants such
as idebenone [40] may be a successful strategy in the
e¡ective treatment of FA.
In summary, the present study has identi¢ed sev-
eral members of the PCIH class of ligands, par-
ticularly PCIH and PCTH, that are highly e⁄-
cient at mobilizing mitochondrial Fe pools. Further
studies on these compounds in animal models are
clearly warranted considering their potential to treat
FA.
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